Immunotherapy: A New Revolutionary Treatment in Cancer
Abstract
Immunotherapy is a type of cancer treatment that aids your immune system to fight cancer. The immune system helps your body fight infections and other diseases. It is made up of white blood cells and organs and tissue of the lymph system. Immunotherapy is a uses substance made from living organisms to treat cancer. 1 Immunotherapy is treatment that focuses on boosting the body’s own immune response against cancer tumors. Cancer cells can be treacherous targets for both therapeutic agent and the body’s natural defense line the immune system. But a new approach to “rewiring macrophages, the body’s pathogen and debris eaters, could offer a fresh boost to cancer immunotherapy. 2
Keywords: Immunotherapy, cancer treatment, immune system, natural defense line
Keywords:
Immunotherapy, immune system, natural defense line, cancer treatmentDOI
https://doi.org/10.22270/jddt.v12i5-S.5666References
Immunotherapy to treat cancer was originally published by November 28, 2018, the National cancer institute.
Reprogramming immune cells to attack cancer tumors, published by Tuesday 22 Jan 2019, written by Maria Cohut.
Cancer - Wikipedia.
Mechanism behind cancer cell growth discovered published September 17, 2013
Link=sciencenordic.com mechanism- behind cancer https://www.healthline.com
https://biomaterialsres.biomedcentral.com/articles/10.1186/s40824-018-0133-y/figures/1
www.pinteres .com (Global News)
Immune cell Transplants could one day lead to new kind of cancer therapy. Published = 28 Dec 2018 written by Rachel Baxter.
Type of cancer immunotherapy - cancer Research UK. Sources = cancer Research UK is registered in England and wales (1089464).
Immunotherapy of cancer- National cancer Institute. https://www.cancer.gov
Jemal A, Bray F, center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA cancer J Clin. 2011; 61(2):69 -90. https://doi.org/10.3322/caac.20107
Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA cancer J Clin. 2011; 61(4):212-236. https://doi.org/10.3322/caac.20121
Urruticoechea A, Alemany R, Balart J, Vinals F,Capella G.Recent advances in cancer therapy: an overview. Curr Pharm Des.2010; 16(1). https://doi.org/10.2174/138161210789941847
Immunotherapy of cancer: an innovative treatment comes of age, written by Yamaguchi, Yoshiyuki, and Tokyo: Sprier [2016].
Immunotherapy of cancer with sensitized T lymphocytes Chang, Alfred E; Shu, Suyu. Austin: Boca Raton, FL: CRC press 1994.
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015; 373:123−135. https://doi.org/10.1056/NEJMoa1504627
Chesney J, Rasku M, Clem A, Miller D. Denileukin diftitox depletes T regulatory cells and causes regression of melanoma metastases in humans. Eur J Cancer Suppl. 2006; 4:12:84. https://doi.org/10.1016/S1359-6349(06)70269-5
Cheung NV. Chapter 32: Therapeutic antibodies and immunologic conjugates. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff's Clinical Oncology. 5th ed. Philadelphia, Pa: Elsevier; 2014.
Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298:850−854. https://doi.org/10.1126/science.1076514
Fry TJ, Mackall CL. T-cell adoptive immunotherapy for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2013; 2013:348−353. https://doi.org/10.1182/asheducation-2013.1.348
Published
Abstract Display: 376 
PDF Downloads: 483 PDF Downloads: 21 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.